The FDA has approved Juvederm Volux XC from Allergan Aesthetics for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. The approval Juvederm Volux XCC marks the sixth product offering in the lineup. In the clinical study, Juvederm Volux XC was found to effectively improve jawline definition at six months. Most treatment group participants reported satisfaction with the appearance of their lower face and jawline through 12 months following treatment. Also, 81.5 percent of participants at six months were satisfied with how sculpted their jawline looked. At six months, 70.5 percent of participants were satisfied with how smooth their lower face looked (i.e., no jowls or folds of fatty skin), and 73.1 percent of participants at six months were satisfied with how nice their lower face looked. Commonly reported side effects in the study included tenderness, lumps/bumps, pain, swelling, firmness, bruising, redness, itching, and discoloration at the injection site. These side effects are consistent with HA filler injection and were usually mild (causing little discomfort and no effect on daily activities) or moderate (causing some discomfort and effect on daily activities) in severity. Most of these side effects went away on their own within two weeks. Allergan Medical Institute will be providing a product training program for Juvederm Volux XC, which will include facial anatomy, considerations for safe injection in this area, appropriate patient selection, and aseptic technique. Training will begin in fall of 2022.